RESUMO
PURPOSE: We aimed to determine the frequency of transient congenital hypothyroidism (TCH) in 17 participating centers in Türkiye, evaluate the etiological distribution in permanent congenital hypothyroidism (PCH) cases, and investigate the role of laboratory and clinical findings in predicting TCH. METHODS: This retrospective observational multicenter study included patients from 17 pediatric endocrinology centers identified by "National Newborn Screening Program" (NNSP) who were born in 2015 and followed for 6 years. Demographic, clinical, and laboratory information of the cases were compiled through the database http://cedd.saglik-network.org (CEDD-NET). RESULTS: Of the 239 cases initially treated for CH, 128 (53.6%) were determined as transient in whom a trial of levothyroxine (LT4) withdrawal was performed at a median age of 36 (34-38) months. Among the patients with PCH (n = 111), thyroid dysgenesis was diagnosed in 39.6% (n = 44). The predictive factors for TCH were: LT4 dose at the withdrawal of treatment, and initial newborn blood screening (NBS)-TSH level. Based on the receiver operating characteristic (ROC) curve analysis to predict optimal cut-offs for TCH predictors, LT4 dose < 2.0 µg/kg/day at treatment discontinuation was predictive for TCH and was associated with 94.5% specificity and 55.7% sensitivity, with an area under the curve (AUC) of 0.802. The initial NBS-TSH level value < 45 µIU/mL was predictive for TCH with 93.1% specificity and 45.5% sensitivity, with an AUC of 0.641. In patients with eutopic thyroid gland only LT4 dose < 1.1 µg/kg/day at withdrawal time was predictive for TCH with 84.7% sensitivity and 40.4% specificity, with an AUC of 0.750. CONCLUSION: According to our national follow-up data, the frequency of TCH was 53.6%. We determined the LT4 dose < 2.0 µg/kg/day at discontinuation of treatment and the initial NBS-TSH level < 45 µIU/mL as the best cut-off limits to predict TCH.
Assuntos
Hipotireoidismo Congênito , Triagem Neonatal , Tiroxina , Humanos , Hipotireoidismo Congênito/tratamento farmacológico , Hipotireoidismo Congênito/diagnóstico , Hipotireoidismo Congênito/sangue , Hipotireoidismo Congênito/epidemiologia , Tiroxina/administração & dosagem , Tiroxina/sangue , Feminino , Triagem Neonatal/métodos , Estudos Retrospectivos , Masculino , Recém-Nascido , Turquia/epidemiologia , Lactente , Seguimentos , Pré-Escolar , PrognósticoRESUMO
OBJECTIVE: Newborn infants, particularly preterm infants, are at greater risk of oxidative stress because of an imbalance between high oxidant loads and immature antioxidant defenses. In several studies, the activities of serum paraoxonase (PON) and arylesterase (ARE) have been found to decline in patients under increased oxidative stress. We investigated the relationships between PON-1 and ARE with fasting and postprandial in premature newborns in this study. PATIENTS AND METHODS: Serum paraoxonase-1 and arylesterase levels were investigated in premature infants less than 37 weeks, after birth while they were fasting and postprandial. RESULTS: The paraoxonase-1 and arylesterase values of infants in fasting were significantly lower than the values in postprandial (for paraoxonase-1, p = 0.034, 0.002, and 0.002, respectively; for arylesterase, p < 0.001, 0.002, and p < 0.001, respectively). CONCLUSIONS: In premature infants, paraoxonase-1 and arylesterase values are increased in postprandial and reduced in fasting, showing that these neonates are subjected to oxidative stress. Thus, starting feeding as soon as possible in premature newborns is vital to protect them from oxidative damage.
Assuntos
Antioxidantes/metabolismo , Arildialquilfosfatase/sangue , Hidrolases de Éster Carboxílico/sangue , Jejum/sangue , Recém-Nascido Prematuro/sangue , Período Pós-Prandial/fisiologia , Biomarcadores/sangue , Feminino , Humanos , Recém-Nascido , Masculino , Estresse Oxidativo/fisiologiaRESUMO
OBJECTIVE: Coeliac disease is a chronic disease and is common all over the world. It has many other associated systemic side effects. This study investigated the effect of paternal and maternal silent coeliac disease on birthweight and gestational age in newborns. METHODS: The study group consisted of 81 newborns who were hospitalized for prematurity or term-intrauterine growth retardation. The parents of premature and/or small for gestational age babies born with coeliac disease-specific antigens were investigated. RESULTS: The differences were not statistically significant in fathers' tissue transglutaminase levels between premature appropriate gestational age, premature small gestational age and term small gestational age infants (p > 0.05), but statistically significant in mothers (p < 0.05). CONCLUSIONS: Silent coeliac disease may occur in parents, especially in mothers of preterm and small for gestational age infants, even in the absence of apparent clinical indications.
RESUMO
We present a male child at 3 years old with Anophthalmia-Plus Syndrome (APS). He has asymmetry of the face and head, left choanal atresia, a sunken facial appearance, microphthalmia in the right eye, severe microphthalmia in the left eye, bilateral low-set ears, scarring from cleft palate surgery. Magnetic resonance imaging (MRI) sections revealed decreased right globe volume, an undeveloped left globe, decreased left optical nerve thickness, Chiari type 2 malformation, left choanal atresia and cleft palate. Echocardiography and abdominal ultrasonography were normal. The patient has a 45 dB conductive hearing loss in the left ear. Repeated thyroid function tests were evaluated as compatible with central hypothyroidism. We report a Fryns Anophthalmia-Plus Syndrome in a child with unusual findings including central hypothyroidism, chiari type 2 malformation, conductive hearing loss and developmental regression. Summary of the features reported in the present case and all 14 previous cases that might be defined as APS.
Assuntos
Anormalidades Múltiplas/diagnóstico , Anoftalmia/diagnóstico , Malformação de Arnold-Chiari/diagnóstico , Deficiências do Desenvolvimento/diagnóstico , Perda Auditiva Condutiva/diagnóstico , Hipotireoidismo/diagnóstico , Pré-Escolar , Humanos , Hipotireoidismo/tratamento farmacológico , Masculino , Tiroxina/uso terapêuticoAssuntos
Humanos , Feminino , Pré-Escolar , Dermatopatias/patologia , Calcinose/patologia , Dermatopatias/terapia , Calcinose/terapia , DietoterapiaRESUMO
An inadequate and imbalanced intake of protein and energy results in protein-energy malnutrition (PEM). It is known that bone mineral density and serum magnesium levels are low in malnourished children. However, the roles of serum magnesium and endothelin-1 (ET-1) levels in the pathophysiology of bone mineralization are obscure. Thus, the relationships between serum magnesium and ET-1 levels and the changes in bone mineral density were investigated in this study. There was a total of 32 subjects, 25 of them had PEM and seven were controls. While mean serum ET-1 levels of the children with kwashiorkor and marasmus showed no statistically significant difference, mean serum ET-1 levels of both groups were significantly higher than that of the control group. Serum magnesium levels were lower than normal value in 9 (36%) of 25 malnourished children. Malnourished children included in this study were divided into two subgroups according to their serum magnesium levels. While mean serum ET-1 levels in the group with low magnesium levels were significantly higher than that of the group with normal magnesium levels (p < 0.05), mean bone mineral density and bone mineral content levels were significantly lower (p < 0.05). In conclusion, many factors play a role in the pathophysiology of changes in bone mineral density in malnutrition. Our study suggested that lower magnesium levels and higher ET-1 levels might be important factors in changes of bone mineral density in malnutrition. We recommend that the malnourished patients, especially with hypomagnesaemia, should be treated with magnesium early.
Assuntos
Densidade Óssea , Endotelina-1/sangue , Magnésio/sangue , Desnutrição Proteico-Calórica/fisiopatologia , Criança , Pré-Escolar , Feminino , Humanos , Kwashiorkor/sangue , Kwashiorkor/fisiopatologia , Masculino , Desnutrição Proteico-Calórica/sangue , Desnutrição Proteico-Calórica/metabolismoRESUMO
Etofenamate is a non-steroidal anti-inflammatory drug (NSAID). Clinical findings caused by etofenamate are uncommon. Allergic contact dermatitis is the most common cutaneous reaction reported. But petechial eruption due to etofenamate had not been reported yet. This report concerns an 11-year old male with petechial eruption after application of topical etofenamate. Physicians need to be aware that patients can develop an asymptomatic purpuric eruption when etofenamate is ordered.
El etofenamato es un antiinflamatorio no esteroideo (AINE). Los hallazgos clínicos sobre los efectos del etofenamato son poco comunes. La dermatitis alérgica por contacto es la reacción cutánea más comúnmente reportada. En cambio, la erupción petequial a causa del etofenamato no se había reportado hasta ahora. Este reporte trata de un varón de 11 años de edad con erupción petequial tras la aplicación del etofenamato tópico. Es necesario que los médicos tomen conciencia de que los pacientes pueden desarrollar una erupción púrpura asintomática, a la hora de prescribir el etofenamato.
Assuntos
Criança , Humanos , Masculino , Anti-Inflamatórios não Esteroides/efeitos adversos , Ácido Flufenâmico/análogos & derivados , Púrpura/induzido quimicamente , Administração Cutânea , Ácido Flufenâmico/efeitos adversosRESUMO
Glucocorticoids have been used in nephrotic syndrome (NS) treatment for many years. In this study, we aimed to evaluate the effect of steroids on bone mineralization in children with glucocorticoid-sensitive nephrotic syndrome (GSNS). Twenty children who were first diagnosed as GSNS received glucocorticoid therapy for four months. Before treatment, at the 4th and 12th week of initial therapy, bone mineral density (BMD) and levels of the markers for bone turnover were evaluated. At the 4th and 12th week of treatment, mean serum calcium (Ca) and osteocalcin levels were found to be significantly lower than those at the beginning ofthe therapy. Mean serum total alkaline phosphatase (t-ALP), bone-specific alkaline phosphatase (b-ALP) and urine calcium creatinine ratio (Ca/Cr), urinary deoxypyridinoline levels were significantly increased in comparison to the beginning of therapy. There was no significant relationship between serum levels of phosphate and parathyroid hormone (PTH) at the beginning of treatment and at the 4th and 12th week of treatment. Mean value of BMD was significantly lower at the 4th and 12th week of treatment than that at the beginning of the therapy. In conclusion, bone mineralization was negatively affected by steroid treatment in children with NS. These children should undergo regular BMD evaluation, and an appropriate therapeutic approach should be planned.
Por muchos años se han venido usando glucocorticoides en el tratamiento del síndrome nefrótico (SN). Este estudio se encamina a evaluar el efecto de los esteroides sobre la mineralización ósea en niños con síndrome nefrótico sensible a los glucocorticoides (SNSG). Veinte niños que fueron diagnosticados primeramente con SNSG, recibieron terapia con glucocorticoides durante cuatro meses. Antes del tratamiento, en las semanas 4 y 12 de la terapia inicial, se evaluaron la densidad mineral ósea (DMO) y los niveles de los marcadores del recambio óseo. En el tratamiento de las semanas 4 y 12, se halló que el calcio (Ca) sérico promedio y los niveles de osteocalcina eran significativamente más bajos que los existentes a comienzos de la terapia. Los niveles de fosfatasa alcalina sérica total promedio, fosfatasa alcalina (t-ALP), fosfatasa alcalina especifica ósea media (b-ALP), la relación calcio/creatinina en la orina (Ca/Cr), y los niveles de deoxipiridinolina urinaria, aumentaron significativamente en comparación con los existentes al comienzo de la terapia. No hubo relación significativa alguna entre los niveles séricos de fosfato y hormona paratiroidea (PTH) ni al principio del tratamiento ni en las semanas 4 y 12 de tratamiento. El valor promedio de la DMO fue significativamente más bajo en las semanas 4 y 12 de tratamiento que al principio de la terapia. En conclusión, la mineralización del hueso fue afectada negativamente por el tratamiento con esteroides en los niños con SN. Estos niños deben tener una evaluación regular de DMO, para lo cual es necesario planear un enfoque terapéutico apropiado.
Assuntos
Criança , Pré-Escolar , Feminino , Humanos , Masculino , Densidade Óssea/efeitos dos fármacos , Glucocorticoides/farmacologia , Síndrome Nefrótica/tratamento farmacológico , Prednisolona/farmacologia , Fosfatase Alcalina/sangue , Aminoácidos/urina , Biomarcadores/sangue , Densidade Óssea/fisiologia , Osso e Ossos/metabolismo , Cálcio/sangue , Cálcio/urina , Creatinina/urina , Glucocorticoides/uso terapêutico , Osteocalcina/sangue , Prednisolona/uso terapêuticoRESUMO
An inadequate and imbalanced intake of protein and energy results in protein-energy malnutrition (PEM). It is known that bone mineral density and serum magnesium levels are low in malnourished children. However, the roles of serum magnesium and endothelin-1 (ET-1) levels in the pathophysiology of bone mineralization are obscure. Thus, the relationships between serum magnesium and ET-1 levels and the changes in bone mineral density were investigated in this study. There was a total of 32 subjects, 25 of them had PEM and seven were controls. While mean serum ET-1 levels of the children with kwashiorkor and marasmus showed no statistically significant difference, mean serum ET-1 levels of both groups were significantly higher than that of the control group. Serum magnesium levels were lower than normal value in 9 (36%) of 25 malnourished children. Malnourished children included in this study were divided into two subgroups according to their serum magnesium levels. While mean serum ET-1 levels in the group with low magnesium levels were significantly higher than that of the group with normal magnesium levels (p < 0.05), mean bone mineral density and bone mineral content levels were significantly lower (p < 0.05). In conclusion, many factors play a role in the pathophysiology of changes in bone mineral density in malnutrition. Our study suggested that lower magnesium levels and higher ET-1 levels might be important factors in changes of bone mineral density in malnutrition. We recommend that the malnourished patients, especially with hypomagnesaemia, should be treated with magnesium early.
El consumo inadecuado y desbalanceado de proteínas y calorías energía conduce a la malnutrición calórico-proteica (MCP). Se sabe que la densidad mineral ósea y los niveles séricos de magnesio son bajos en los ninos malnutridos. Sin embargo, no está claro el papel que desempenan los niveles séricos de magnesio y los niveles séricos de endotelina-1 (ET-1) en la patofisiología de la mineralización del hueso. Por consiguiente, las relaciones entre los niveles séricos de magnesio y los niveles séricos de ET-1, y los cambios en la densidad mineral ósea, constituyen el objeto de investigación de este estudio. Hubo un total de 32 sujetos; 25 de ellos tenían DCP y 7 eran considerados. Si bien los niveles séricos promedios de ET-1 de los ninos con kwashiorkor y marasmo no mostraron diferencia estadística significativa, los niveles séricos promedio de ET-1 de ambos grupos fueron significativamente más altos que los del grupo de control. Los niveles séricos de magnesio estuvieron por debajo del valor normal en 9 (36%) de 25 ninos malnutridos. Los ninos malnutridos incluidos en este estudio fueron divididos en dos sub-grupos según sus niveles de magnesio en suero. Mientras que los niveles séricos promedio de ET-1 en el grupo con niveles bajos de magnesio fueron significativamente más altos que los del grupo con niveles normales de magnesio (p < 0.05), la densidad mineral ósea promedio y los niveles promedio del contenido mineral óseo fueron significativamente más bajos (p < 0.05). En conclusión, muchos factores juegan un papel en la patofisiología de los cambios en la densidad mineral ósea por la malnutrición. Nuestro estudio sugirió niveles más bajos de magnesio y niveles más altos de ET-1 podrían ser factores importantes en los cambios de densidad mineral ósea en la malnutrición. Se recomienda que los pacientes malnutridos, especialmente a causa de hipomagnesemia, sean tratados con magnesio lo más pronto posible.
Assuntos
Criança , Pré-Escolar , Feminino , Humanos , Masculino , Densidade Óssea , Endotelina-1/sangue , Magnésio/sangue , Desnutrição Proteico-Calórica/fisiopatologia , Kwashiorkor/sangue , Kwashiorkor/fisiopatologia , Desnutrição Proteico-Calórica/sangue , Desnutrição Proteico-Calórica/metabolismoRESUMO
Etofenamate is a non-steroidal anti-inflammatory drug (NSAID). Clinical findings caused by etofenamate are uncommon. Allergic contact dermatitis is the most common cutaneous reaction reported. But petechial eruption due to etofenamate had not been reported yet. This report concerns an 11-year old male with petechial eruption after application of topical etofenamate. Physicians need to be aware that patients can develop an asymptomatic purpuric eruption when etofenamate is ordered.
Assuntos
Anti-Inflamatórios não Esteroides/efeitos adversos , Ácido Flufenâmico/análogos & derivados , Púrpura/induzido quimicamente , Administração Cutânea , Criança , Ácido Flufenâmico/efeitos adversos , Humanos , MasculinoRESUMO
Glucocorticoids have been used in nephrotic syndrome (NS) treatment for many years. In this study, we aimed to evaluate the effect of steroids on bone mineralization in children with glucocorticoid-sensitive nephrotic syndrome (GSNS). Twenty children who were first diagnosed as GSNS received glucocorticoid therapy for four months. Before treatment, at the 4th and 12th week of initial therapy, bone mineral density (BMD) and levels of the markers for bone turnover were evaluated. At the 4th and 12th week of treatment, mean serum calcium (Ca) and osteocalcin levels were found to be significantly lower than those at the beginning of the therapy. Mean serum total alkaline phosphatase (t-ALP), bone-specific alkaline phosphatase (b-ALP) and urine calcium creatinine ratio (Ca/Cr), urinary deoxypyridinoline levels were significantly increased in comparison to the beginning of therapy There was no significant relationship between serum levels of phosphate and parathyroid hormone (PTH) at the beginning of treatment and at the 4th and 12th week of treatment. Mean value of BMD was significantly lower at the 4th and 12th week of treatment than that at the beginning of the therapy In conclusion, bone mineralization was negatively affected by steroid treatment in children with NS. These children should undergo regular BMD evaluation, and an appropriate therapeutic approach should be planned.
Assuntos
Densidade Óssea/efeitos dos fármacos , Glucocorticoides/farmacologia , Síndrome Nefrótica/tratamento farmacológico , Prednisolona/farmacologia , Fosfatase Alcalina/sangue , Aminoácidos/urina , Biomarcadores/sangue , Densidade Óssea/fisiologia , Osso e Ossos/metabolismo , Cálcio/sangue , Cálcio/urina , Criança , Pré-Escolar , Creatinina/urina , Feminino , Glucocorticoides/uso terapêutico , Humanos , Masculino , Osteocalcina/sangue , Prednisolona/uso terapêuticoRESUMO
Recurrent parotitis is an acute, severe inflammation of one or both parotid glands, the major salivary glands in young children. We report the case of a seven-year old boy with Primary Sjogrens syndrome (PSS) who presented with 15 episodes of painful recurrent bilateral swellings of the parotid glands over a four-year period.
La parotitis recurrente es una inflamación aguda, severa y reiterada de una o ambas glándulas parótidas - la mayor de las glándulas salivares - en los niños pequeños. Se reporta el caso de un niño de siete años de edad con el síndrome de Sjögren primario (SSP). El niño presentó 15 episodios de dolorosas inflamaciones bilaterales recurrentes de las glándulas parótidas por un período de cuatro años.
Assuntos
Criança , Humanos , Masculino , Parotidite/diagnóstico , Síndrome de Sjogren/diagnóstico , Antirreumáticos/uso terapêutico , Diagnóstico Diferencial , Glucocorticoides/uso terapêutico , Metotrexato/uso terapêutico , Parotidite/tratamento farmacológico , Prednisolona/uso terapêutico , RecidivaRESUMO
Recurrent parotitis is an acute, severe inflammation of one or both parotid glands, the major salivary glands in young children. We report the case of a seven-year old boy with Primary Sjogrens syndrome (PSS) who presented with 15 episodes of painful recurrent bilateral swellings of the parotid glands over a four-year period.
Assuntos
Parotidite/diagnóstico , Síndrome de Sjogren/diagnóstico , Antirreumáticos/uso terapêutico , Criança , Diagnóstico Diferencial , Glucocorticoides/uso terapêutico , Humanos , Masculino , Metotrexato/uso terapêutico , Parotidite/tratamento farmacológico , Prednisolona/uso terapêutico , RecidivaRESUMO
DRESS syndrome (drug reaction with eosinophilia and systemic symptoms), previously named "drug hypersensitivity syndrome", is a severe adverse drug reaction characterized by skin rash, fever, lymph node enlargement and internal organ involvement. We report on a 7-year old girl who developed DRESS syndrome caused by penicillin V treatment.
El síndrome DRESS (así llamado por las indíciales del inglés "drug reaction with eosinophilia y systemic symptoms ") es una reacción a medicamentos, acompañada por eosinofilia y síntomas sistémicos. Conocida anteriormente como "síndrome de hipersensibilidad a los medicamentos, se trata de una reacción adversa severa a los medicamentos, caracterizada por erupción cutánea, fiebre, agrandamiento de los ganglios y compromiso de órganos internos. El presente trabajo reporta el caso de una niña de 7 años de edad, que desarrolló el síndrome DRESS a partir de un tratamiento con penicilina V.
Assuntos
Criança , Feminino , Humanos , Antibacterianos/efeitos adversos , Toxidermias/etiologia , Eosinofilia/induzido quimicamente , Febre/induzido quimicamente , Doenças Linfáticas/induzido quimicamente , Penicilina V/efeitos adversos , Diagnóstico Diferencial , Toxidermias/diagnóstico , Hipersensibilidade a Drogas , Eosinofilia/diagnóstico , Febre/diagnóstico , Doenças Linfáticas/diagnóstico , Faringite/tratamento farmacológico , Síndrome , Tonsilite/tratamento farmacológicoRESUMO
The aim of this study is to evaluate the acquisition of bone mineral in healthy children throughout puberty and in children with constitutional delay of growth and puberty (CDGP), and to relate changes in bone mass to age, weight, height, sitting height, body mass index and sex hormones in healthy boys. A total of 90 boys: 15 boys with CDGP and 75 healthy boys in different pubertal stages were examined. The number of children assigned to each Tanner stages was 15. Although bone age, weight and Body Mass Index (BMI) were significantly higher in stages II, III, IV, V compared to stage I and CDGP, mean height and sitting height values were higher in stages III, IV, V compared to stage I and CDGP. Also, serum FSH, LH, oestradiol, total and free testosterone levels progressively increased, although serum sex hormone binding globulin (SHBG) levels decreased, in healthy children with progression of sexual development. Significant increase was observed for serum oestradiol levels at stage II and above (p < 0.001), for serum total and free testosterone levels at stage III and above (p < 0.001), for serum FSH and LH levels at stage IV and above (p < 0.01 and p < 0.001) respectively. Also, it was shown that bone mineral content (BMC) and bone mineral density (BMD) measurements were significantly higher for pubertal stage lll and above groups according to both the CDGP group and stage I group. When BMD and BMC measurements of children with CDGP (0.62 ± 0.05 gr/cm² and 23.4 ± 2.8 gr) were compared with bone age, age, BMI and height-matched controls, there was no significant difference between children with CDGP and controls, except for age. Bone mineral density and BMC measurements in children with CDGP were significantly lower than those of age-matched controls (for pubertal stage lll: p < 0.05, for pubertal stage IV: p < 0.01). The strongest correlation coefficients were found between BMD and height among auxological parameters (r = 0.63, p < 0.001) and serum oestradiol levels among hormones (r = 0.55, p < 0.001). The most important findings of this investigation was the determination of body composition and hormonal measurement changes during puberty in boys; oestradiol was the most potent determinant of BMD among pubertal boys. We suggested that there is a critical age period for accumulation of bone mass according to the results. Longitudinal studies will elucidate why sufficient mineralization does take place after puberty starts in CDGP.
El objetivo de este estudio es evaluar la adquisición de mineral óseo del hueso en niños saludables a través de la pubertad y en niños varones con retraso constitucional del crecimiento y la pubertad (RCCP), y relacionar los cambios de masa ósea a la edad, el peso, la altura, la altura sentado, el índice de masa corporal, y las hormonas del sexo en niños varones saludables. Examinamos un total de 90 niños, 15 niños con RCCP y 75 niños saludables en diferentes etapas de la pubertad. El número de niños asignados a cada etapa de Tanner fue 15. Aunque la edad ósea, el peso y el IMC fueron significativamente más altos en las etapas II, III, IV, V, comparados con la etapa I y el RCCP; la altura promedio y los valores de la altura sentado fueron más altos en las etapas III, IV, V, comparados con la etapa I y el RCCP. Por otra parte, los niveles séricos de HEF, HL, estradiol y testosterona total y libre, aumentaron progresivamente, aunque los niveles séricos de SHBG disminuyeron en los niños saludables con el avance del desarrollo sexual. Se observó un aumento significativo en los niveles de estradiol sérico en la etapa II y por encima (p <0.001), en los niveles séricos de testosterona libre y total en la etapa II y por encima (p < 0.001), y en los niveles séricos de HEF, HL en la etapa IV y por encima (p < 0.01 y p < 0.001). Además se observó que las mediciones del contenido mineral óseo (CMO) y la densidad mineral ósea (DMO) fueron significativamente mayores en la etapa III de la pubertad y grupos por encima, de acuerdo tanto con el grupo de RCCP cómo el grupo de la etapa I. Cuando las mediciones de DMO y CMO de niños con RCCP (0.62 ± 0.05 gr/cm² y 23.4 ± 2.8 gr) fueron comparadas con la edad ósea, la edad, IMC y los controles pareados por altura, no se halló ninguna diferencia significativa entre los niños con RCCP y los controles, excepto la edad. Las mediciones de DMO y CMO en niños con RCCP fueron significativamente más bajas que las de los controles pareados por edad (para la etapa III de la pubertad: p < 0.05; para la etapa IV de la pubertad: p < 0.01). Los coeficientes de correlación más fuertes se encontraron entre la DMO y la altura entre los parámetros auxológicos (r = 0.63, p < 0.001), los niveles séricos de estradiol entre las hormonas (r = 0.55, p < 0.001). Los hallazgos más importantes de esta investigación fueron la determinación de la composición corporal y los cambios en la medición hormonal durante la pubertad en los muchachos; el estradiol fue el determinante más potente de la DMO entre los niños en la pubertad. Sugerimos que hay un periodo de edad crítico para la acumulación de masa ósea de acuerdo con nuestros resultados. Los estudios longitudinales esclarecerán por qué se produce suficiente mineralización después de que la pubertad empieza en RCCP.
Assuntos
Criança , Humanos , Masculino , Densidade Óssea/fisiologia , Estradiol/sangue , Transtornos do Crescimento/sangue , Puberdade Tardia/sangue , Puberdade/fisiologia , Antropometria , Composição Corporal , Hormônio Foliculoestimulante/sangue , Hormônio Luteinizante/sangue , Testosterona/sangueRESUMO
DRESS syndrome (drug reaction with eosinophilia and systemic symptoms), previously named "drug hypersensitivity syndrome", is a severe adverse drug reaction characterized by skin rash, fever lymph node enlargement and internal organ involvement. We report on a 7-year old girl who developed DRESS syndrome caused by penicillin V treatment.